KR20220038767A - 항-egfr/항-4-1bb 이중 특이 항체 및 이의 용도 - Google Patents

항-egfr/항-4-1bb 이중 특이 항체 및 이의 용도 Download PDF

Info

Publication number
KR20220038767A
KR20220038767A KR1020227006641A KR20227006641A KR20220038767A KR 20220038767 A KR20220038767 A KR 20220038767A KR 1020227006641 A KR1020227006641 A KR 1020227006641A KR 20227006641 A KR20227006641 A KR 20227006641A KR 20220038767 A KR20220038767 A KR 20220038767A
Authority
KR
South Korea
Prior art keywords
ser
gly
val
thr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227006641A
Other languages
English (en)
Korean (ko)
Inventor
용예령
정의정
정혜진
박경수
손원준
이양순
김연주
성은실
김영광
박영돈
박민지
엄재현
최효주
송무영
이나래
박영봉
이은정
Original Assignee
에이비엘바이오 주식회사
주식회사유한양행
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이비엘바이오 주식회사, 주식회사유한양행 filed Critical 에이비엘바이오 주식회사
Publication of KR20220038767A publication Critical patent/KR20220038767A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020227006641A 2019-07-26 2020-07-27 항-egfr/항-4-1bb 이중 특이 항체 및 이의 용도 Pending KR20220038767A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962878977P 2019-07-26 2019-07-26
US62/878,977 2019-07-26
PCT/KR2020/009870 WO2021020845A1 (en) 2019-07-26 2020-07-27 Anti-egfr/anti-4-1bb bispecific antibody and use thereof

Publications (1)

Publication Number Publication Date
KR20220038767A true KR20220038767A (ko) 2022-03-29

Family

ID=74189704

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227006641A Pending KR20220038767A (ko) 2019-07-26 2020-07-27 항-egfr/항-4-1bb 이중 특이 항체 및 이의 용도

Country Status (11)

Country Link
US (2) US12168690B2 (https=)
EP (1) EP4004053A4 (https=)
JP (2) JP7738545B2 (https=)
KR (1) KR20220038767A (https=)
CN (2) CN118221825A (https=)
AU (1) AU2020320349A1 (https=)
BR (1) BR112022001329A2 (https=)
CA (1) CA3147420A1 (https=)
MX (1) MX2022001027A (https=)
WO (1) WO2021020845A1 (https=)
ZA (1) ZA202200905B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024237519A1 (ko) * 2023-05-12 2024-11-21 앱클론(주) 항체 또는 그의 항원 결합 단편, 및 어피바디를 포함하는 이중 항원 표적 단백질 복합체
KR102927129B1 (ko) 2025-03-18 2026-02-11 이트너스 주식회사 임직원 공간 산정을 위한 사무 및 부대 시설 면적 계산 솔루션

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211147A1 (es) 2019-08-12 2021-06-28 I Mab Biopharma Us Ltd Anticuerpos anti-claudina 18.2 y anti-4-1bb biespecificos y su uso
EP4434548A1 (en) 2021-11-15 2024-09-25 Systimmune, Inc. Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof
US20250320309A1 (en) * 2021-11-25 2025-10-16 Shenghe (China) Biopharmaceutical Co., Ltd. Bispecific antigen binding protein
JP2025512915A (ja) * 2022-04-07 2025-04-22 ユハン コーポレーション Ｈｅｒ２の発現レベルが低いがんを治療又は予防するための薬学的組成物
JP2025542406A (ja) * 2022-12-30 2025-12-25 アブクロン・インコーポレイテッド Ｃｄ１３７に特異的に結合するアフィボディ及びその用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2185770T3 (es) * 1995-04-08 2003-05-01 Lg Chemical Ltd Anticuerpo monoclonal especifico para 4-1bb humano y linea celular que lo produce.
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
AU2006211037B2 (en) 2005-02-07 2012-05-24 Roche Glycart Ag Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
SI2073842T1 (sl) * 2006-09-10 2015-05-29 Glycotope Gmbh Uporaba človeških celic izvirajočih iz mieloične levkemije za izražanje protiteles
DK2699598T3 (en) * 2011-04-19 2019-04-23 Pfizer COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
JP6539275B2 (ja) * 2013-08-16 2019-07-03 メモリアル スローン ケタリング キャンサー センター 選択的ｇｒｐ９４阻害剤およびその使用
SG11201704741PA (en) * 2014-12-22 2017-07-28 Systimmune Inc Bispecific tetravalent antibodies and methods of makiing and using thereof
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
FI3436048T3 (fi) 2016-03-31 2025-09-15 Biontech Us Inc Neoantigeeneja ja niiden käyttömenetelmiä
AU2017252233A1 (en) * 2016-04-22 2018-11-15 Alligator Bioscience Ab Novel bispecific polypeptides against CD137
CN118267470A (zh) * 2017-04-13 2024-07-02 赛罗帕私人有限公司 抗SIRPα抗体
SG11202000503QA (en) * 2017-07-20 2020-02-27 Aptevo Res & Development Llc Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
WO2019129644A1 (en) * 2017-12-28 2019-07-04 Julius-Maximilians-Universität Würzburg TUMOR NECROSIS FACTOR (TNF) RECEPTOR SUPERFAMILY (TNFRSF) RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FcγR-INDEPENDENT AGONISTIC ACTIVITY (TNFRSF RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCγR-INDEPENDENT AGONISTIC ACTIVITY; TRAAFFIAA)
CN119798453A (zh) * 2018-11-13 2025-04-11 Jn生物科学有限责任公司 激活免疫细胞的双特异性抗体
CN113286825B (zh) * 2018-11-30 2024-06-18 爱必乐生物公司 抗pd-l1/抗4-1bb双特异性抗体及其用途
PE20211147A1 (es) * 2019-08-12 2021-06-28 I Mab Biopharma Us Ltd Anticuerpos anti-claudina 18.2 y anti-4-1bb biespecificos y su uso
CA3169943A1 (en) * 2020-02-28 2021-09-02 Shanghai Henlius Biotech, Inc. Anti-cd137 constructs, multispecific antibody and uses thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024237519A1 (ko) * 2023-05-12 2024-11-21 앱클론(주) 항체 또는 그의 항원 결합 단편, 및 어피바디를 포함하는 이중 항원 표적 단백질 복합체
KR102927129B1 (ko) 2025-03-18 2026-02-11 이트너스 주식회사 임직원 공간 산정을 위한 사무 및 부대 시설 면적 계산 솔루션

Also Published As

Publication number Publication date
JP2022542670A (ja) 2022-10-06
CN118221825A (zh) 2024-06-21
MX2022001027A (es) 2022-04-18
JP2026004296A (ja) 2026-01-14
CA3147420A1 (en) 2021-02-04
AU2020320349A1 (en) 2022-02-17
US20250066487A1 (en) 2025-02-27
CN114450306A (zh) 2022-05-06
JP7738545B2 (ja) 2025-09-12
US20210024638A1 (en) 2021-01-28
EP4004053A4 (en) 2023-10-18
CN114450306B (zh) 2024-04-05
US12168690B2 (en) 2024-12-17
ZA202200905B (en) 2023-11-29
BR112022001329A2 (pt) 2022-03-22
EP4004053A1 (en) 2022-06-01
WO2021020845A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
KR102820082B1 (ko) 항-her2/항-4-1bb 이중 특이 항체 및 이의 용도
US20250066487A1 (en) Anti-egfr/anti-4-1bb bispecific antibody and use thereof
US10246507B2 (en) Polypeptide, anti-VEGF antibody, and anti-c-Met/anti-VEGF bispecific antibodies comprising the same
TW202208438A (zh) 抗ｌｉｌｒｂ１抗體或其抗原結合片段、製備其的方法、藥物組成物、核酸分子、重組載體以及重組細胞
CN115785268A (zh) 抗cd47抗体及其用途
US10000569B2 (en) Anti-cMet/anti-EGFR/anti-HER3 multispecific antibodies and use thereof
CN114829405A (zh) 抗bcma/抗4-1bb双特异性抗体及其用途
RU2831836C2 (ru) Биспецифическое антитело анти-egfr/анти-4-1вв и его применение
RU2831838C2 (ru) Биспецифическое антитело анти-HER2/анти-4-1BB и его применение
HK40072153A (en) Anti-egfr/anti-4-1bb bispecific antibody and use thereof
HK40072153B (zh) 抗egfr/抗4-1bb双特异性抗体及其用途
US20250215112A1 (en) Pharmaceutical composition for treating or preventing cancer with low expression level of her2
HK40071708A (en) Anti-her2/anti-4-1bb bispecific antibody and use thereof
HK40071708B (zh) 抗her2/抗4-1bb双特异性抗体及其用途
KR101926834B1 (ko) 항-dr5 항체 및 그의 용도
HK40113710A (zh) 用於治疗或预防her2低表达水平的癌症的药物组合物
HK40078173B (zh) 抗bcma/抗4-1bb双特异性抗体及其用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902